Galderma reported three-year Nemluvio data as Galderma stock joined SMI

Published on 10/09/2026 at 11:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half sales rose 24.60 percent to USD 3.10 billion. Galderma stock was EUR 176.85 on October 9, 2026 versus EUR 175.33, plus 0.87 percent.

Key points in brief

Galderma reported three-year Nemluvio data on September 30, 2026, with up to 91.00 percent of patients achieving EASI-75.
First-half 2026 net sales rose 24.60 percent at constant currency to USD 3.10 billion, while full-year guidance reached 19.00-21.00 percent.
Galderma stock was trading at EUR 176.85 at Lang & Schwarz on October 9, 2026, plus 0.87 percent versus EUR 175.33.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma (ISIN CH1335392721) reported three-year Nemluvio data on September 30, 2026, with up to 91.00 percent of patients achieving at least 75.00 percent improvement in eczema severity. FinanzNachrichten carried the release. The company had joined the Swiss Market Index on September 21, 2026, while raising its full-year sales growth guidance to 19.00-21.00 percent from 17.00-20.00 percent.

Three milestones changed the case

On April 22, 2026, shareholders approved a gross dividend of CHF 0.35 per dividend-bearing share at the annual meeting, according to Galderma. On September 21, 2026, the company entered the SMI and reported first-half sales growth of 24.60 percent at constant currency, according to Business Wire. The September 30 Nemluvio update is the latest of the three events.

What does Nemluvio mean for growth?

The clinical data add support to Galderma's therapeutic dermatology strategy, but the financial test is commercial scale. Management said first-half 2026 Nemluvio sales reached USD 433.00 million, while therapeutic dermatology sales rose 67.90 percent at constant currency.

Galderma's first-half net sales reached USD 3.10 billion, up 24.60 percent at constant currency, and core EBITDA reached USD 802.00 million, up 42.80 percent. Core EBITDA margin was 25.60 percent, an improvement of 3.28 percentage points from the first half of 2025, according to the Yahoo Finance transcript. The same call said Nemluvio sales could pass USD 1.00 billion in 2026.

Next dates for Galderma

Galderma's next quarterly results are scheduled for October 22, 2026, according to Daily Digest Invest. A fourth-quarter 2026 results date of March 11, 2027, was listed by finanzen.ch.

Galderma stock holds near its yearly high

Galderma stock was trading at EUR 176.85 at Lang & Schwarz on October 9, 2026 at 11:06 a.m. CEST, plus 0.87 percent versus the prior close of EUR 175.33 on October 8, 2026. On SIX, the stock was last at CHF 165.00 on October 9, 2026 at 10:54 a.m. CEST; its 52-week range was CHF 134.70 to CHF 188.25.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.